Show simple item record

dc.contributor.authorDjebbari, Faouzi
dc.contributor.authorRampotas, Alexandros
dc.contributor.authorVallance, Grant
dc.contributor.authorPanitsas, Fotios
dc.contributor.authorBasker, Nanda
dc.contributor.authorSangha, Gina
dc.contributor.authorSalhan, Beena
dc.contributor.authorKarim, Farheen
dc.contributor.authorAl-Kaisi, Firas
dc.contributor.authorGudger, Amy
dc.contributor.authorNgu, Loretta
dc.contributor.authorPoynton, Matt
dc.contributor.authorLam, Ho Pui Jeff
dc.contributor.authorMorgan, Lowri
dc.contributor.authorYang, Laura
dc.contributor.authorYoung, Jennifer
dc.contributor.authorWalker, Mairi
dc.contributor.authorTsagkaraki, Ismini
dc.contributor.authorAnderson, Laura
dc.contributor.authorChauhan, Saleena Rani
dc.contributor.authorMaddams, Rebecca
dc.contributor.authorSoutar, Richard
dc.contributor.authorTriantafillou, Margarita
dc.contributor.authorPrideaux, Steve
dc.contributor.authorObeidalla, Abubaker
dc.contributor.authorBygrave, Ceri
dc.contributor.authorBasu, Supratik
dc.contributor.authorRamasamy, Karthik
dc.date.accessioned2022-05-09T09:40:43Z
dc.date.available2022-05-09T09:40:43Z
dc.date.issued2022-05-30
dc.identifier.citationDjebbari, F., Rampotas, A., Vallance, G. et al. (2022) Efficacy of isatuximab with pomalidomide and dexamethasone in relapsed myeloma: Results of a UK-wide real-world dataset. HemaSphere, 6(6), e738.en
dc.identifier.issn2572-9241en
dc.identifier.doi10.1097/HS9.0000000000000738
dc.identifier.urihttp://hdl.handle.net/2436/624746
dc.description© 2022 The Authors. This is an open access article available under a Creative Commons licence. The published version can be accessed at the following link on the publisher’s website: http://dx.doi.org/10.1097/HS9.0000000000000738en
dc.description.abstractReal-world data on the efficacy and tolerability of isatuximab with pomalidomide and dexamethasone (IsaPomDex) in relapsed/refractory myeloma (RRMM) patients have not been reported. In this UK-wide retrospective study, IsaPomDex outcomes were evaluated across 24 routine care cancer centres. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), duration of response (DOR) for patients who achieved an objective response (≥PR), and adverse events (AEs). In a total cohort 107 patients, median follow up (IQR) was 12.1 months (10.1-18.6 months), median age (IQR) was 69 years (61-77). Median (IQR) Charlson Co-morbidity index (CCI) score was 3 (2- 4); 43% had e-GFR<60 ml/min. Median (IQR) number of prior therapies was 3 (3-3). Median (IQR) number of IsaPomDex cycles administered was 7 (3-13). ORR was 66.4%, with responses categorised as ≥VGPR: 31.8%, PR: 34.6%, SD: 15.9%, PD: 15% and unknown 2.8%. Median PFS was 10.9 months. Median DOR was 10.3 months There was no statistical difference in median PFS by age (<65: 10.2 vs. 65-74 13.2 vs. ≥75: 8.5 months, log-rank p=0.4157), by CCI score (<4: 10.2 months vs. ≥4: 13.2, log-rank p=0.6531), but inferior PFS was observed with renal impairment (≥60: 13.2 vs. <60: 7.9 months, log-rank p=0.0408). Median OS was 18.8 months. After a median of 4 cycles, any grade AEs were experienced by 87.9% of patients. The most common ≥G3 AEs were neutropenia (45.8%), infections (18.7%) and thrombocytopenia (14%). Our UK-wide IsaPomDex study demonstrated encouraging efficacy outcomes in the real-world, comparable to ICARIA-MM trial.en
dc.formatapplication/pdfen
dc.language.isoenen
dc.publisherLippincott, Williams & Wilkinsen
dc.relation.urlhttps://journals.lww.com/hemasphere/pages/default.aspxen
dc.subjectisatuximaben
dc.subjectpomalidamideen
dc.subjectdexamethasoneen
dc.subjectmyelomaen
dc.titleEfficacy of isatuximab with pomalidomide and dexamethasone in relapsed myeloma: Results of a UK-wide real-world dataseten
dc.typeJournal articleen
dc.identifier.journalHemaSphereen
dc.date.updated2022-05-03T13:55:34Z
dc.identifier.articlenumbere738
dc.date.accepted2022-05-02
rioxxterms.funderUniversity of Wolverhamptonen
rioxxterms.identifier.projectUOW09052022SBen
rioxxterms.versionVoRen
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2022-05-30en
dc.source.volume6
dc.source.issue6
refterms.dateFCD2022-05-09T09:40:18Z
refterms.versionFCDVoR
refterms.dateFOA2022-05-31T03:44:01Z


Files in this item

Thumbnail
Name:
Efficacy_of_Isatuximab_With_Po ...
Size:
714.6Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

https://creativecommons.org/licenses/by-nc-nd/4.0/
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by-nc-nd/4.0/